Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00476216 · ClinicalTrials.gov registry record · Phase 1
Fondaparinux (Arixtra) With Chemotherapy for Advanced Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT00476216 is a Phase 1 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 23 participants.
The verdict
NCT00476216, a Phase 1 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
There is a direct association between cancer and thrombosis (blood clots). The purpose of this study is to determine the best dose of an antithrombotic (prevents blood clots) agent called fondaparinux in non-small cell lung cancer(NSCLC). Patients will also receive chemotherapy.
Interventions
- DRUG Combination of Arixtra with chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2007-09 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00476216
The ClinicalTrials.gov registry entry for NCT00476216 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Combination of Arixtra with chemotherapy is the first listed.
NCT00476216 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00476216 about?
NCT00476216 is a clinical study titled "Fondaparinux (Arixtra) With Chemotherapy for Advanced Non-Small Cell Lung Cancer". There is a direct association between cancer and thrombosis (blood clots). The purpose of this study is to determine the best dose of an antithrombotic (prevents blood clots) agent called fondaparinux in non-small cell lung cancer(NSCLC). Patients will also receive chemotherapy.
What is the current status of trial NCT00476216?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2007-09. Estimated completion is 2013-12.
What interventions are being tested in trial NCT00476216?
The interventions under investigation include: Combination of Arixtra with chemotherapy (DRUG).
Who is sponsoring clinical trial NCT00476216?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.